First-line treatment for advanced pancreatic cancer

Journal of the Pancreas

Volumn 12, Issue 2, 2011, Pages 96-100

  Oberstein, Paul E ^a   Saif, Muhammad Wasif ^a  

^a New York Presbyterian Hospital ^*  (United States)

Author keywords

Drug therapy; Erlotinib; Gemcitabine; Pancreatic neoplasms

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DNA TOPOISOMERASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LAPATINIB; OXALIPLATIN; PANITUMUMAB; PLACEBO; SORAFENIB; TAXANE DERIVATIVE; VASCULOTROPIN; VENOM;

ADVANCED CANCER; ANTICOAGULATION; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER GROWTH; DRUG MECHANISM; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTESTINE PERFORATION; METASTASIS; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; RASH; SEPSIS; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; MEDICINE, CHINESE TRADITIONAL; PANCREATIC NEOPLASMS; PYRIDINES; QUINAZOLINES; TREATMENT OUTCOME;

EID: 79952784459     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300.
2. Surveillance Epidemiology and End Results (SEER). U.S. Cancer Statistics: 1999-2007 Incidence and Mortality Report. Available at http://www.seer.cancer.gov/publications/uscs.html (Accessed January 31, 2011).
3. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-2413.
4. Gubens MA, Kunz PL, Fisher GA, Ford JM, Lichtensztajn D, Clarke CA. Long-term survivorship in pancreatic adenocarcinoma. J Clin Oncol 2011; 29 (Suppl. 4):Abstract 175.
5. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nature Reviews Clinical Oncology 2010;7: 163-172.
6. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-1966.
7. Conroy T, Desseigne F, Ychou M, Ducreux M, Bouche O, Guimbaud R, et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE. J Clin Oncol 2010; 28(15 Suppl):4010.
8. G. P. Kim, N. R. Foster, M. Salim, et al. Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma. J Clin Oncol 2011; 29(Suppl. 4):Abstract 238.
9. S. Candamio Folgar, C. Méndez Méndez, M. Jorge Fernández, et al. A phase II study of capecitabine in combination with erlotinib as first-line therapy in patients with metastatic pancreatic cancer (stage IV). J Clin Oncol 2011; 29(Suppl. 4):Abstract 277.
10. Cunningham D, Chau I, Stocken DD, et al. Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. J Clin Oncol 2009 Nov 20;27(33):5513-5518.
11. R. S. McDermott, P. Calvert, M. Parker, et al. A phase II study of lapatinib and capecitabine in first-line treatment of metastatic pancreatic cancer (ICORG 08- 39). J Clin Oncol 2011; 29 (Suppl. 4):Abstract 315.
12. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
13. Munoz Llarena, J. Mane, G. Lopez-Vivanco, et al. Gemcitabine(G) fixed-dose-rate infusion (FDR) plus erlotinib (E) in patients with advanced pancreatic cancer (APC). J Clin Oncol 2011; 29(Suppl. 4):Abstract 304.
14. D. J. Cohen, L. P. Leichman, E. Love, et al. Phase II study of sorafenib with gemcitabine and erlotinib (GES) in first-line advanced pancreatic cancer. J Clin Oncol 2011; 29(Suppl. 4):Abstract 266.
15. Khorana AA, Frine RL. Pancreatic cancer and thromboembolic disease. Lancer Oncol 2004; 5:655-663.
16. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007 May 15;13(10):2870-2875.
17. Nitori N, Ino Y, Nakanishi Y, et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 2005;11:2531-2539.
18. R. K. Ramanathan, V. Gressler, S. Shah, et al. Phase I/II study of PCI-27483, a coagulation factor VIIa (FVIIa) inhibitor in patients with advanced pancreatic cancer receiving treatment with gemcitabine. J Clin Oncol 2011; 29(Suppl. 4):Abstract 221.
19. Z. Meng, L. Liu, Y. Shen, et al. A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC). J Clin Oncol 2011; 29(Suppl. 4):Abstract 284.
20. Philip PA, Benedetii J, Fenoglio-Preiser M, et al. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic Adenocarcinoma: SWOG S0205 study. J Clin Oncol 2007; 25(20 Suppl): Abstract:LBA4509.
21. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009 Aug 10;27(23):3778-3785.
22. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010 Aug 1;28(22):3617-3622.
23. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009 May 1;27(13):2231-2237.
24. J. C. Bendell, S. Britton, M. R. Green, et al. Immediate impact of the FOLFIRINOX phase III data reported at the 2010 ASCO Annual Meeting on prescribing plans of American oncology physicians for patients with metastatic pancreas cancer (MPC). J Clin Oncol 2011; 29 (Suppl. 4):Abstract 286.